» Articles » PMID: 19375688

Vitreous Penetration of Orally Administered Famciclovir

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2009 Apr 21
PMID 19375688
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To determine the vitreous penetration of penciclovir (Denavir; GlaxoSmithKline, Philadelphia, Pennsylvania, USA) after oral administration of the prodrug famciclovir (Famvir; Novartis Pharmaceuticals Corp, East Hanover, New Jersey, USA).

Design: Prospective interventional case series.

Methods: Ten patients undergoing elective pars plana vitrectomy at a single institution were enrolled to take 3 oral doses of famciclovir 500 mg the day preceding surgery and a fourth dose on the morning of surgery. Blood and undiluted vitreous samples were acquired from each patient during surgery. High-performance liquid chromatography was used to determine the concentration of penciclovir in each sample. Exclusion criteria included prior vitrectomy, compromised blood-retina barrier, renal or hepatic disease, human immunodeficiency virus infection, bone marrow or renal transplantation, pregnancy or breastfeeding, history of adverse reaction or allergy to famciclovir or penciclovir, and antiviral, probenecid, or cimetidine use within 1 month of surgery.

Results: Ten eyes of 10 patients ranging in age from 26 to 82 were included. All patients had normal renal and hepatic function as determined by history and laboratory values. Mean serum penciclovir concentration +/- standard deviation was 4.45 +/- 1.31 microg/ml (range, 2.51 to 6.34 microg/ml). Mean vitreous penciclovir concentration was 1.21 +/- 0.38 microg/ml (range, 0.39 to 1.88 microg/ml). Mean vitreous-to-serum concentration ratio of penciclovir was 0.28 +/- 0.09 (range, 0.16 to 0.41).

Conclusions: Oral administration of famciclovir results in vitreous concentrations of penciclovir within the inhibitory ranges for herpes simplex 1, herpes simplex 2, and varicella zoster virus. Oral famciclovir may be a reasonable alternative to intravenous acyclovir (Zovirax; GlaxoSmithKline) in the treatment of acute retinal necrosis, especially in cases of acyclovir resistance or patient inability to tolerate prolonged intravenous treatment.

Citing Articles

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.

Afarid M, Mahmoodi S, Baghban R J Nanobiotechnology. 2022; 20(1):361.

PMID: 35918688 PMC: 9344723. DOI: 10.1186/s12951-022-01567-7.


Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.

Kim H, Woo S Pharmaceutics. 2021; 13(1).

PMID: 33467779 PMC: 7830424. DOI: 10.3390/pharmaceutics13010108.


Antimicrobial guide to posterior segment infections.

Patel T, Zacks D, Dedania V Graefes Arch Clin Exp Ophthalmol. 2020; 259(9):2473-2501.

PMID: 33156370 DOI: 10.1007/s00417-020-04974-4.


New Therapeutic Perceptions in a Patient with Complicated Herpes Simplex Virus 1 Keratitis: A Case Report and Review of the Literature.

Kalogeropoulos D, Geka A, Malamos K, Kanari M, Kalogeropoulos C Am J Case Rep. 2017; 18:1382-1389.

PMID: 29279602 PMC: 5753617. DOI: 10.12659/ajcr.906506.


Long-term outcomes in patients undergoing vitrectomy for retinal detachment due to viral retinitis.

Almeida D, Chin E, Tarantola R, Tegins E, Lopez C, Boldt H Clin Ophthalmol. 2015; 9:1307-14.

PMID: 26229423 PMC: 4514312. DOI: 10.2147/OPTH.S87644.